key: cord-0776326-j16rzl0j
authors: Hammer, Mark M.; Hunsaker, Andetta R.; Gooptu, Mahasweta; Hatabu, Hiroto
title: Frequency of Pulmonary Embolism in Patients with COVID-19
date: 2020-10-03
journal: JACC Cardiovasc Imaging
DOI: 10.1016/j.jcmg.2020.09.006
sha: 79341b2e9b2553cbcf0a03723c80c7f4bb41e191
doc_id: 776326
cord_uid: j16rzl0j

nan

Several reports have highlighted a high incidence of pulmonary embolism (PE) in patients with COVID-19 (1) (2) (3) (4) . However, patients with severe illness, particularly those in the intensive care unit, have increased D-dimer levels and high risk of venous thromboembolism. It is not clear if the high risk of PE reported in some series simply reflects severe illness, or if COVID-19 itself confers a particularly high risk of thromboembolism. We thus set out to evaluate the rate of PE in patients with COVID-19 compared to controls who were tested but found to be negative for the virus.

This retrospective study was approved by the institutional review board. Patients in our healthcare system who received COVID-19 RT-PCR testing between March 1, 2020 and May 1, 2020 and underwent CT pulmonary angiography (CTPA) within 7 days prior to and 14 days after the testing were included. Radiology reports and D-dimer levels within 1 day of the CTPA were retrieved from the electronic medical record. Clinical pretest probability of PE was derived from order indications. The presence of an endotracheal tube was extracted from radiology reports.

CTPA reports were recorded as positive for PE, negative, or non-diagnostic. Non-diagnostic studies were excluded.

Statistical analysis was performed with JMP Pro (v15, SAS Institute, Cary, NC).

Differences between categorical variables were analyzed with one-tailed Fisher's exact test and continuous variables with one-tailed t-test. Multivariable logistic regression was used to evaluate determinants of a positive CTPA. Confidence intervals (CI) for area under the receiver operating characteristic curves (AUC) were generated by bootstrapping.

A total of 709 CTPAs were identified; 13 non-diagnostic studies were excluded, leaving 696 CTPAs from 674 patients. The median age was 63 (range 17 -100), 352 (52%) were female, and 167 (25%) were COVID-19 positive. Pretest probability was available for 475 (68%) of J o u r n a l P r e -p r o o f Our results show that COVID-19 status did not predict PE, with the biggest risk factor being elevated D-dimer. We found substantially lower rates of PE in our COVID-19 positive cohort (12%) than that reported in other studies (22-30%) (1, 2, 4) . This may be related to higher severity of disease in those studies. Indeed, in the subgroup of intubated patients in our study, the rate of PE was 30%, comparable to the 21% in a study focused exclusively on COVID-19 J o u r n a l P r e -p r o o f patients in intensive care(3). Among our intubated patients, those with COVID-19 did have a higher rate of PE than those without COVID-19, but this did not reach statistical significance.

However, the number of intubated patients in our study was quite low, limiting our statistical power. It is possible that the pro-thrombotic state reported in COVID-19 patients is associated with greater severity of disease, leading to the sickest patients having higher rates of PE. Of note, patients with severe pandemic H1N1 influenza were also shown to have an increased rate of PE(5).

We did find a greater risk of PE within 1 day of COVID-19 testing. It may be that patients with COVID-19 are given more prophylactic anticoagulation than non-COVID-19 cases, leading to a lower risk of PE later in their disease course. Alternatively, it is possible that the small numbers of patients with CTPAs later in the disease course precluded detection of a difference at later timepoints.

This study has several limitations, most notably that it is retrospective. The population was selected for patients who underwent CTPAs, which itself introduces bias. However, we do note that our PE rates are lower than in other reports, suggesting that our study is likely less biased than some others. Finally, we did not record use of anticoagulation, which would impact risk of developing thromboembolism. However, the practice guidelines in our hospital system recommend routine prophylactic anticoagulation for all COVID-19 inpatients.

In summary, we found that the risk of PE was much lower than previously reported in patients with COVID-19, although, there was an increased risk of PE around the time of PCR test positivity. There is mounting evidence of a pro-thrombotic state in COVID-19 patients.

However, it remains to be elucidated whether COVID-19 produces a unique pro-thrombotic pathophysiology or simply drives thrombosis through severe inflammation.

J o u r n a l P r e -p r o o f

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography

Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels

Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence

Acute Pulmonary Embolism and COVID-19

Chest Radiographic and CT Findings in Novel Swine-Origin Influenza A (H1N1) Virus (S-OIV) Infection